key: cord-0699464-k2sprhtj
authors: Park, Sung Yong; Faraci, Gina; Ward, Pamela M.; Emerson, Jane F.; Lee, Ha Youn
title: High-precision and cost-efficient sequencing for real-time COVID-19 surveillance
date: 2021-07-01
journal: Sci Rep
DOI: 10.1038/s41598-021-93145-4
sha: e815f952e40795790d27df9838049913c7161c55
doc_id: 699464
cord_uid: k2sprhtj

COVID-19 global cases have climbed to more than 33 million, with over a million total deaths, as of September, 2020. Real-time massive SARS-CoV-2 whole genome sequencing is key to tracking chains of transmission and estimating the origin of disease outbreaks. Yet no methods have simultaneously achieved high precision, simple workflow, and low cost. We developed a high-precision, cost-efficient SARS-CoV-2 whole genome sequencing platform for COVID-19 genomic surveillance, CorvGenSurv (Coronavirus Genomic Surveillance). CorvGenSurv directly amplified viral RNA from COVID-19 patients’ Nasopharyngeal/Oropharyngeal (NP/OP) swab specimens and sequenced the SARS-CoV-2 whole genome in three segments by long-read, high-throughput sequencing. Sequencing of the whole genome in three segments significantly reduced sequencing data waste, thereby preventing dropouts in genome coverage. We validated the precision of our pipeline by both control genomic RNA sequencing and Sanger sequencing. We produced near full-length whole genome sequences from individuals who were COVID-19 test positive during April to June 2020 in Los Angeles County, California, USA. These sequences were highly diverse in the G clade with nine novel amino acid mutations including NSP12-M755I and ORF8-V117F. With its readily adaptable design, CorvGenSurv grants wide access to genomic surveillance, permitting immediate public health response to sudden threats.

Precision and accuracy of CorvGenSurv. We measured the accuracy of CorvGenSurv by sequencing the genomic RNA of the USA-WA1/2020 control strain (GenBank: MN985325.1) provided by BEI Resources (NR-52285). The assembled near full-length SARS-CoV-2 sequence obtained by CorvGenSurv matched 100% to the sequence of this control strain. This accuracy was achieved by our error correction step during consensus sequence building. To assess how many reads are required to produce an accurate consensus sequence, we performed a bootstrap test, randomly sampling a given number of reads and building the consensus sequence of those reads. As shown in Fig. 1b , when three reads were sampled, only 67% [52.4-78 .9%] of the 1000 bootstrap runs' resulting consensus sequences were consistent with the reference sequence of USA-WA1/2020. When we generated a consensus sequence from 31 or more reads, the consensus sequence of all 1000 bootstrap runs was identical to the control sequence. This 31-fold sequencing depth ensured the production of a SARS-CoV-2 whole genome sequence that perfectly matched the control sequence.

We also spot-checked the precision of CorvGenSurv by Sanger sequencing, the current gold standard for precision checking 34 . USA/CA-LAC-USC1 in Table 1 was selected, and a near full-length SARS-CoV-2 sequence was obtained by assembling a total of 49 overlapping segments that were sequenced by Sanger sequencing. The resulting Sanger sequence matched 100% to the corresponding USA/CA-LAC-USC1 sequence obtained by CorvGenSurv.

We observed two putative deletions in one sequence (USA/CA-LAC-USC2) that potentially originated from homopolymer sequencing errors. However, these errors were rare as we observed only two deletions out of 754,702 base calls (2.65 × 10 -6 per base). We have thus corrected these putative errors.

COVID-19 patients who tested positive at Keck Medicine of USC Clinical Laboratories by accessing their remnant NP/OP swab specimens. This study (HS-20-00326) was approved by the Institutional Review Board of the University of Southern California. Table 1 presented each specimen's collection date from April to June 2020 and COVID-19 test cycle threshold (C t ) values. diagnostic testing were subject to SARS-CoV-2 RNA extraction. Viral RNA was amplified via three overlapping RT-PCRs (~ 10,000 base long each) and pooled SARS-CoV-2 amplicons of indexed COVID-19 specimens were then sequenced by long-read high-throughput single-molecule sequencing. The output fasta file was de-multiplexed and processed to produce the consensus sequence of each segment. Each COVID-19 specimen's three overlapping segments were assembled into a SARS-CoV-2 whole genome sequence. (b) CorvGenSurv's precision was tested by comparing the consensus sequence from a given number of reads with the USA-WA1/2020 control strain (GenBank: MN985325.1). When a consensus sequence was built from three reads, only 67% [52.4-78 .9%] of the 1000 bootstrap runs' resulting consensus sequences were consistent with the correct sequence. When the number of the reads was greater or equal to 31, all 1000 bootstrap runs resulted in the correct sequence. www.nature.com/scientificreports/ Figure 2a presented the maximum likelihood tree of these 25 Los Angeles sequences along with 1,215 sequences from the state of California archived in GISAID 20,21 as of July 27th, 2020. The most recent common ancestor sequence of the 25 strains (grey circle in Fig. 2a ) had three nucleotide substitutions from the reference sequence, Wuhan-Hu-1, and two amino acid changes, P323L in the RNA-dependent RNA polymerase (RdRP, NSP12) and D614G in the S protein 12, 35 . As expected, sequences of specimens collected from April to May (purple numbers in Fig. 2a) were located closer to the root of tree than those of specimens collected in June (blue numbers in Fig. 2a ). Ten of the 25 sequences shared additional mutations of R203K and G204R in the N (nucleocapsid) protein (skyblue circle in Fig. 2a) as part of the GR-clade 20, 21 . Eight other sequences had mutations of T85I in the NSP2 protein and Q57H in the ORF3a protein (red circle in Fig. 2a) as part of the GH-clade 20, 21 . Five other sequences shared the mutation S194L in the N protein (purple circle in Fig. 2a) as part of the G-clade 20,21 . One sequence (USA/CA-LAC-USC15) had a unique mutation lineage amongst the sampled 25 sequences as part of the G-clade 20, 21 (Fig. 2a) . Another sequence (USA/CA-LAC-USC16) had a unique mutation lineage as part of the GH clade 20, 21 . These 25 sequences reflect the high viral diversity observed in California within the G, GR, and GH clades 35, 36 . Figure 2b marked the amino acid changes of each of our 25 sequences in reference to the Wuhan-Hu-1 sequence. We reported a total of nine new amino acid mutations that were not observed among 28,176 global SARS-CoV-2 sequences in GISAID 20, 21 . These include M755I in RdRP (NSP12) and V117F in the ORF8 protein (Table 1) .

We compared the prevalence of each amino acid mutation from Wuhan-Hu-1 that had greater than 2% frequency either globally, in the USA, or in California as of July, 2020 (Fig. 2c) . Mass circulation of G clade strains Table 1 . Amino acid mutations, clade and lineage of 25 whole genome sequences from COVID-19 remnant NP/OP specimens. Novel amino acid mutations that were not observed among 28,176 global SARS-CoV-2 sequences in GISAID are in bold. C t -1 targeted the ORF1/a-b non-structural region and C t -2 a conserved region in the structural protein envelope E-gene. qRT-PCR was performed using the Roche COBAS system. www.nature.com/scientificreports/ were confirmed by around 80% prevalence of P323L in RdRP and D614G in the S protein globally. In USA and California, the prevalence of T85I in NSP2 and Q57H in ORF3a were observed to be above 40%, as shown in Fig. 2c . The prevalence of P1263L mutation in the S protein was sixfold greater in California than the global prevalence. Additionally, S194L mutation in the N protein was much more prevalent in California, compared to other regions.

CorvGenSurv's supply cost. The development of a cost-effective SARS-CoV-2 genotyping protocol is crucial to expanding COVID-19 surveillance efforts. The per-specimen supply cost of our SARS-CoV-2 whole genome sequencing method was estimated to be $33.8. This includes RNA extraction from NP/OP swab media ($4.58), long-range RT-PCR ($25.8), index PCR ($2.6), and long-read high-throughput sequencing ($0.82). We estimated the per-specimen high-throughput sequencing cost by assessing the maximum number of specimens ( N m ) we can process in a single sequencing run. We observed that 31 or more reads would be required to produce an accurate consensus sequence (Fig. 1b) . Therefore, we estimated how many reads are required on average to obtain a minimum of 31 reads per consensus sequence. The expected minimum value of N g Poisson random variables is given by ∞ k=1 [γ (k, )/ Ŵ(k)] N g , where is the mean of the Poisson distribution, γ (k, ) is the lower incomplete gamma function, and Ŵ(k) is the gamma function. Since we need three segments per specimen, N g is given by 3 × N m . We obtained around 1.58 million circular consensus sequence (CCS) reads Table 1 were denoted by 1 to 25 in this tree. All 25 sequences were classified as G clade with mutations P323L in NSP12 (RdRP) and D614G in S protein (grey circle). Different ancestral sequences were presented by circles in different colors with common mutations of each lineage presented in the box. The unit branch length (one nucleotide base substitution) was denoted as "HD = 1". (b) Each of our 25 sequences' amino acid mutations from Wuhan-Hu-1 (MN908947) were marked using Highlighter (https:// www. hiv. lanl. gov/ conte nt/ seque nce/ HIGHL IGHT/ highl ighter_ top. html). The regions of NSP2, NSP12 (RdRP), S, E, M, and N were presented by colored boxes. (c) The prevalence of each amino acid mutation with greater than 2% frequency either globally, in the USA, or in California. A total of 28,176 global sequences were downloaded from GISAID 20,21 . www.nature.com/scientificreports/ with 99% accuracy for a library size of ~ 10 kb from a single sequencing run. We estimated that 8779 specimens can be processed in a single sequencing run, where 60 reads per consensus sequence can be obtained on average to recover a minimum of 31 reads per consensus sequence. Similarly, if we aim to recover a minimum of 100 reads per consensus sequence as a conservative approach, around 3657 specimens can be processed in a single sequencing run. Assuming a sequencing cost of $3000, this yields a per specimen sequencing cost of $0.82 for large-scale sequencing efforts. This estimated low-sequencing cost suggests a cost advantage over current short-read based SARS-CoV-2 whole genome sequencing methods 8,10-12,26-30 . The required time for CorvGenSurv is around 15 h for sample library preparation and 30 h for sequencing. Our cost-effective workflow may therefore enhance the implementation of real-time massive genomic SARS-CoV-2 surveillance.

We estimated the rate of SARS-CoV-2 evolution from the 25 genomes we obtained using a Bayesian phylogenetic reconstruction method 37, 38 . The SARS-CoV-2 nucleotide evolution rate was estimated to be 7.51 The rate of SARS-CoV-2 evolution was also estimated by measuring the rate of divergence from the reference Wuhan-Hu-1 sequence. We plotted our sequences' number of nucleotide base differences from the Wuhan-Hu-1 sequence against sample collection time difference in Fig. 3 . The nucleotide substitution rate in reference to Wuhan-Hu-1 was measured to be 8.62 × 10 -4 substitutions per site per year (95% confidence interval: 7.96 × 10 -4 to 9.24 × 10 -4 ). This rate was consistent with the above Bayesian phylogenetic estimate.

can potentially escape from vaccine-induced immunity 16, 17 . The emergence and circulation of such variants has prompted efforts to continuously monitor SARS-CoV-2 evolution via real-time genomic surveillance 39, 40 . To further demonstrate its importance, we analyzed influenza evolution in response to vaccination. Influenza has also been shown to escape from vaccine-induced immunity, as confirmed by serologic testing 41 . The WHO changed the 2019-2020 H1N1 Northern Hemisphere Flu vaccine strain from A/Michigan/45/2015 (grey diamond in Fig. 4a-c) to A/Brisbane/02/2018 (purple diamond in Fig. 4a-c) 42 . Our maximum likelihood tree analysis showed that influenza H1NI Hemagglutinin (HA) sequences evolved away from this new vaccine strain. As shown in Fig. 4a , a total of 255 H1N1 Hemagglutinin (HA) sequences sampled in April 2019 were relatively close to the 2019-2020 H1N1 vaccine strain (purple diamond in Fig. 4a) . However, we found that HA sequences collected in January 2020 (1140 sequences total) had evolved away from this vaccine strain. This rapid evolution was visualized in a two-dimensional map obtained by multidimensional scaling of the pairwise HA sequence distance matrix (Fig. 4b,c) . As plotted in Fig. 4d , the nucleotide base difference from the vaccine sequence was significantly higher among the January 2020 sequences, compared to the April 2019 sequences (median distance 18 vs. 23, p < 0.001). www.nature.com/scientificreports/ This observed evolution away from the vaccine strain may explain the 2019-2020 seasonal influenza vaccine's low effectiveness against influenza A (H1N1). Influenza vaccine efficacy was estimated to be 37% against H1N1 strains during the 2019-20 flu season 43 . Viral evolution in response to vaccination remains a challenge for vaccine design, and the 2019-20 flu season highlights the need for real-time surveillance of viral sequences. Like influenza, SARS-CoV-2 has the potential to evolve in response to vaccination 44 , and thus SARS-CoV-2 evolution must be continuously monitored in real time to prevent vaccine failure and guide future vaccine strain selection.

We developed CorvGenSurv (Coronavirus Genomic Surveillance), a streamlined, high-resolution, and costeffective SARS-CoV-2 whole genome sequencing method in which viral RNA is directly amplified, indexed, and sequenced. CorvGenSurv's precision and accuracy have been validated by Sanger sequencing and control genomic RNA sequencing, respectively. Our targeted amplification of the whole genome in three segments minimized the risk of genome coverage dropouts. Additionally, our streamlined long-read sequencing protocol significantly reduced workflow complexity and thus has a potential cost advantage over currently available shortread sequencing approaches 8, [10] [11] [12] [26] [27] [28] 31 .

We obtained 25 whole genome sequences from NP/OP remnant COVID-19 positive test specimens that were collected from April to June 2020 at Los Angeles County, California, USA. The Los Angeles County pandemic accounted for 33% of all COVID-19 cases in California with around 3500 new cases per day in July 2020 45,46 . Our maximum likelihood tree analysis showed that the 25 strains were highly diverse within the G, GR and GH clades 35 . The G clade and tis lineage have been dominant since late March, 2020 and its D614G mutation in the spike protein has been associated with increased transmissibility 14 . In addition to the G clade's other common mutation, NSP12-P323L, frequent mutations we observed include N-S194L, N-R203K, N-G204R, NSP2-T85I, and ORF3a-Q57H. From this wide spectrum of viral mutations, we estimated SARS-CoV-2 evolutionary rate by a Bayesian phylogenetic reconstruction method 37, 38 and divergence measures. These two estimates were 7.51 × 10 -4 and 8.62 × 10 -4 substitutions per site per year respectively, which were consistent with recent reports on the SARS-CoV-2 evolutionary rate [47] [48] [49] .

We identified new amino acid mutations in the NSP3, NSP4, RdRP (NSP12), ORF8, and N proteins. Mutations in these proteins have the potential to trigger immune escape, alter viral replication capacity, or modulate viral immune suppression. Numerous T cell epitopes have been annotated in these proteins and thus mutations can lead to viral escape from cellular immune responses 50, 51 . While mutations in the N, NSP3, NSP4 or NSP12 proteins can alter viral replication capacity 13,52-55 , those in the ORF8 or N proteins may dysregulate host innate www.nature.com/scientificreports/ immune responses via type I interferon signal modulation 54 . It is therefore of great importance to monitor mutations from a diverse array of proteins by whole genome sequencing to pinpoint those that are relevant to viral pathogenicity and immune escape. SARS-CoV-2's S protein is the key target for many of the vaccines currently in development 18 and thus mutations in this region are being closely monitored for their potential to render these vaccines ineffective. The observed influenza HA sequence evolution away from this year's vaccine strain clearly indicates the necessity of screening mutations in viral surface proteins. Genomic surveillance data can also inform SARS-CoV-2 drug resistance. Mutations in RdRP (NSP12) can potentially result in decreased binding affinity with nucleoside analogs such as Remdesivir and Favipiravir 56 . Therefore, genomic surveillance on circulating pandemic strains is crucial for guiding strategies for COVID-19 vaccination and therapeutic intervention and our simple and cost-efficient pipeline has the potential to advance real-time COVID-19 surveillance.

CorvGenSurv can accurately survey new mutations in real-time and thus provide crucial data for disease transmission, new outbreak detection, and vaccine candidate selection. As an alternative to the more common short-read sequencing approaches 8, [10] [11] [12] [26] [27] [28] [29] [30] , CorvGenSurv can facilitate the widespread adoption of real-time COVID-19 genomic surveillance and can therefore serve as an important tool for public health decision-making. www.nature.com/scientificreports/

This study (HS-20-00326) was approved by the Institutional Review Board of the University of Southern California as non-human subjects research. Table 1 lists each specimen's collection date and cycle threshold (C t ) values for the ORF1 a/b non-structural SARS-CoV-2 unique region (C t -1) and the pan-Sarbecovirus

The sequences were globally aligned using MUSCLE 57 , and their 5'-and 3'-ends trimmed-out, yielding a 597-29340 segment of the Wuhan-Hu-1 reference strain. We removed any sequences that were shorter than this region and sequences with one or more ambiguous bases to obtain a total of 28,176 near full-length SARS-CoV-2 sequences, including 9339 originating from the USA and 1215 from California

As listed in Supplementary Table S1, the RT-PCR primers were 1_LEFT/33_RIGHT or For-c/Rev-c for the first segment, Ford/67_RIGHT or 33_LEFT/67_RIGHT for the second segment, and 67_LEFT/Rev-e or 67_LEFT/98_RIGHT for the third segment. Here, 1_LEFT, 33_RIGHT, 33_LEFT, 67_RIGHT, 67_LEFT, and 98_RIGHT were the ARTIC network primers (V3, https:// artic. netwo rk/ ncov-2019), where the "nCoV-2019_" suffix was removed for simplicity. Primers, For-c, Rev-c, For-d, and Rev-e were designed in-house. These primers span the near full-length SARS-CoV-2 genome in three segments with overlap for genome assembly. The master mix was composed of 25 μl RT-PCR master mix, 2.5 μl each of 10 μM forward and reverse primers, 0.5 μl SuperScript IV RT mix, and 19.5 μl of viral RNA to a total volume of 50 μl. The samples were cycled according to the manufacturer's instructions: 50 °C for 10 min of RT, followed by 98 °C for 2 min for RT inactivation, then 35 cycles of 98 °C for 10 s, 55 °C for 10 s, 72 °C for 5 min, then a final extension of 72 °C for 5 min, held at 4 °C until the next step. The RT-PCR products were then purified and concentrated with Ampure XP beads (Beckman Coulter) with a 0.8 × bead volume, two 70% ethanol washes, and elution in 25 μl Nuclease-Free H 2 O. These purified RT-PCR products were subjected to long-range index PCR using PrimeSTAR GXL DNA Polymerase (Takara Bio) according to the manufacturer's instructions. After index PCR

Purified RT-PCR product for each of the three segments of USA/CA-LAC-USC1 was amplified via long-range PCR with the master mix composed of 10 μl of PrimeSTAR GXL buffer, 4 μl of dNTPs, 2.5 μl each of 2 μM forward and reverse primers, 1 μl of PrimeSTAR GXL DNA polymerase, 26 μl nuclease free H 2 O, and 4.0 μl of purified RT-PCR product to a total volume of 50 μl. The samples PCR cycled with 25 cycles of 98 °C for 10 s and 68 °C for 10 min, held at 4 °C until the next step. These products were Ampure cleaned with a 0.8 × bead volume and diluted to 20 ng/μl. A total of 10 μl of the diluted product was combined with 5 μl of each Sanger sequencing primer in 5 μM

From public health genomics to precision public health: A 20-year journey

HIV infection linked to injection use of oxymorphone in Indiana

Whole-genome sequencing and social-network analysis of a tuberculosis outbreak

Real-time, portable genome sequencing for Ebola surveillance

Rapid outbreak sequencing of Ebola virus in Sierra Leone identifies transmission chains linked to sporadic cases

Genomic and Epidemiological Surveillance of Zika Virus in the Amazon Region

Spread of SARS-CoV-2 in the Icelandic population

Investigation of three clusters of COVID-19 in Singapore: Implications for surveillance and response measures

Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands

Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling

A new coronavirus associated with human respiratory disease in China

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

The race for coronavirus vaccines: A graphical guide

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial

Data, disease and diplomacy: GISAID's innovative contribution to global health

Global initiative on sharing all influenza data-From vision to reality

Nextstrain: Real-time tracking of pathogen evolution

Variable influenza vaccine effectiveness by subtype: A systematic review and meta-analysis of test-negative design studies

Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by eggadapted vaccine strains

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Multiple approaches for massively parallel sequencing of SARS-CoV-2 genomes directly from clinical samples

Introductions and early spread of SARS-CoV-2 in the New York City area

Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: A prospective genomic surveillance study

Rapid, sensitive, full-genome sequencing of severe acute respiratory syndrome coronavirus 2. Emerg

Rapid high throughput whole genome sequencing of SARS-CoV-2 by using one-step RT-PCR amplification with integrated microfluidic system and next-gen sequencing

Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples

Real-time DNA sequencing from single polymerase molecules

Accurate circular consensus long-read sequencing improves variant detection and assembly of a human genome

DNA sequencing with chain-terminating inhibitors

Geographic and genomic distribution of SARS-CoV-2 mutations

Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California

Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. Virus Evol

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic

Sequence analysis of 20,453 severe acute respiratory syndrome coronavirus 2 genomes from the Houston metropolitan area identifies the emergence and widespread distribution of multiple isolates of all major variants of concern

Monitor for COVID-19 vaccine resistance evolution during clinical trials

The evolution of seasonal influenza viruses

How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past

No evidence for distinct types in the evolution of SARS-CoV-2

Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

A Sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2

The coronavirus nucleocapsid is a multifunctional protein

Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein

The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway

Two-amino acids change in the nsp4 of SARS coronavirus abolishes viral replication

Coronavirus susceptibility to the antiviral Remdesivir (GS5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Multiple sequence alignment with high accuracy and high throughput

CAP3: A DNA sequence assembly program

A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood

We thank the Molecular Pathology Division of the USC Keck Clinical Laboratories for providing the remnant NP/OP specimens that are sequenced in this study. The genomic RNA of USA-WA1/2020 strain was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: Genomic RNA from SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52285. We thank Dr. Jing-Hsiung James Ou, Dr. Sarah Hamm-Alvarez, and Dr. Thomas Buchanan for their help. We thank all laboratories and authors who shared global SARS-CoV-2 whole genome sequences and influenza H1NI Hemagglutinin (HA) sequences by depositing to GISAID's EpiFlu (TM) Database.

H.L. and S.P. conceived this project, designed the experimental workflows and bioinformatics pipelines, and performed sequence analysis. G.F. conducted SARS-CoV-2 whole genome sequencing. P.W. and J.E. provided COVID-19 remnant specimens sequenced in this study.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-93145-4.Correspondence and requests for materials should be addressed to H.Y.L.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.